Advantage Alpha Capital Partners LP Has $5.96 Million Stake in Encompass Health Corporation $EHC

Key Points

• Advantage Alpha Capital Partners LP decreased its holdings in Encompass Health Corporation by 21.9%, owning 58,863 shares after selling 16,477 shares in the first quarter.
• Several institutional investors increased their positions in Encompass Health, with First Trust Advisors LP boosting its shares by 20.1% to 284,774 shares valued at $26.3 million.
• Analysts have generally upgraded their ratings for Encompass Health, with a consensus rating of "Buy" and an average target price of $134.00.

Advantage Alpha Capital Partners LP trimmed its stake in shares of Encompass Health Corporation (NYSE:EHC - Free Report) by 21.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 58,863 shares of the company's stock after selling 16,477 shares during the quarter. Encompass Health makes up 1.5% of Advantage Alpha Capital Partners LP's portfolio, making the stock its 14th biggest position. Advantage Alpha Capital Partners LP owned 0.06% of Encompass Health worth $5,962,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC bought a new position in Encompass Health during the 1st quarter valued at $263,000. GAMMA Investing LLC raised its holdings in shares of Encompass Health by 21.5% during the first quarter. GAMMA Investing LLC now owns 2,366 shares of the company's stock worth $240,000 after purchasing an additional 419 shares during the period. Sequoia Financial Advisors LLC raised its holdings in shares of Encompass Health by 6.7% during the first quarter. Sequoia Financial Advisors LLC now owns 2,727 shares of the company's stock worth $276,000 after purchasing an additional 172 shares during the period. Cambridge Investment Research Advisors Inc. increased its holdings in shares of Encompass Health by 30.1% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 9,597 shares of the company's stock worth $972,000 after acquiring an additional 2,218 shares during the period. Finally, Fifth Third Bancorp increased its holdings in shares of Encompass Health by 88.7% in the 1st quarter. Fifth Third Bancorp now owns 4,290 shares of the company's stock worth $434,000 after acquiring an additional 2,017 shares during the period. 97.25% of the stock is currently owned by institutional investors.

Encompass Health Price Performance

Shares of NYSE:EHC traded down $0.36 during trading hours on Tuesday, hitting $121.83. 763,029 shares of the company's stock traded hands, compared to its average volume of 816,086. Encompass Health Corporation has a 52 week low of $87.85 and a 52 week high of $124.67. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06. The company's fifty day simple moving average is $116.41 and its two-hundred day simple moving average is $110.56. The company has a market cap of $12.27 billion, a price-to-earnings ratio of 23.84, a price-to-earnings-growth ratio of 2.15 and a beta of 0.86.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.20. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The business's revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.11 EPS. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. As a group, equities analysts anticipate that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Encompass Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Wednesday, October 1st will be paid a $0.19 dividend. The ex-dividend date of this dividend is Wednesday, October 1st. This represents a $0.76 dividend on an annualized basis and a yield of 0.6%. This is a positive change from Encompass Health's previous quarterly dividend of $0.17. Encompass Health's dividend payout ratio (DPR) is 14.87%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on EHC shares. Royal Bank Of Canada increased their price objective on shares of Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a report on Monday, April 28th. Truist Financial raised their target price on shares of Encompass Health from $135.00 to $140.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Wall Street Zen cut shares of Encompass Health from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. KeyCorp raised their target price on shares of Encompass Health from $122.00 to $135.00 and gave the company an "overweight" rating in a research note on Tuesday, May 27th. Finally, Stephens raised shares of Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 target price on the stock in a research note on Thursday, June 5th. One analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat, Encompass Health presently has a consensus rating of "Buy" and an average target price of $134.00.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.